Gene Editing Market Report 2025

The gene editing market size has grown rapidly in recent years. It will grow from $8.82 billion in 2024 to $10.34 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to discovery of crispr-cas9, advancements in genetic sequencing, medical breakthroughs, scientific research funding, biotechnology industry growth.

The gene editing market size is expected to see rapid growth in the next few years. It will grow to $20.79 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to therapeutic applications expansion, precision and efficiency enhancements, gene therapy commercialization, agricultural applications development, regenerative medicine growth. Major trends in the forecast period include multiplex editing techniques, base editing innovations, gene drives and population modification, non-viral delivery systems, disease modeling and drug discovery.

The rising prevalence of communicable diseases is driving growth in the gene editing market, as gene editing techniques become essential for the detection and treatment of these illnesses. Communicable diseases, which result from infectious agents like bacteria, viruses, or parasites, can spread between people, animals, or through environmental exposure. Gene editing technologies are increasingly used to create targeted methods for identifying and neutralizing pathogens at the genetic level, thus enhancing disease management and prevention. For example, in 2023, the World Economic Forum, a Switzerland-based international non-governmental organization, reported an increase in infections such as influenza and respiratory syncytial virus (RSV) since the pandemic. In the USA, by February 2023, influenza alone led to an estimated 24 million illnesses, 260,000 hospitalizations, and 16,000 deaths. Additionally, in 2022, the World Health Organization reported that 10.6 million people worldwide were infected with tuberculosis, resulting in 1.3 million deaths. Consequently, the prevalence of communicable diseases is fueling the growth of the gene editing market.

The global gene editing market is expected to witness growth due to the rising incidence of genetic disorders. Genetic disorders result from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. These disorders can lead to various health issues, either present at birth or developing later in life. Gene editing offers substantial potential in addressing severe genetic diseases such as sickle cell disease, Huntington's disease, β-thalassemia, cystic fibrosis, Alzheimer's, and Parkinson's. For example, the National Library of Medicine (NLM) reported an estimated 6.7 million Americans aged 65 and older living with Alzheimer's dementia (AD) in 2023. The prevalence is projected to increase to 13.8 million by 2060 unless medical breakthroughs intervene. Genetic disorders are on the rise, and the application of gene editing technologies is expected to drive market growth.

Infectious diseases continue to pose a significant threat globally, causing more than 17 million deaths annually, as reported by the World Health Organization (WHO). Public sentiment reflects the growing acceptance of gene editing for the treatment of incurable, hereditary diseases, with 71% of surveyed adults in the US expressing support for its use, according to the AP-NORC survey. Additionally, 67% of Americans endorse gene editing for disease prevention, including conditions such as cancer. This positive perception underscores the potential of gene editing technologies in addressing various health challenges and contributing to market growth.

Major companies are introducing innovative technologies, such as a technique based on special cell-penetrating peptides, which offers advantages over existing methods. In April 2023, Penn Medicine, a prominent US-based multi-hospital health system, discovered that protein fragments used by certain viruses to enter cells could also facilitate the efficient and low-toxicity delivery of CRISPR-Cas gene editing molecules into cells and their DNA-containing nuclei. This breakthrough holds potential for developing advanced cell therapies for diseases such as cancer. The technique is particularly promising for modifying T cells and other patient-derived cells for applications such as CAR T (chimeric antigen receptor T cell) therapy, a specialized immunotherapy for cancer treatment. This new genetic engineering approach promises improvements in speed, efficiency, and reduced cellular toxicity compared to current methods.

The emergence of advanced genome editing techniques stands out as a major trend in the gene editing market. These techniques, characterized by their cost-effectiveness, find applications in diverse fields, including agriculture to enhance the food supply, rectifying specific genetic mutations in the human genome, and preventing the spread of diseases. One notable genome editing technique is CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats), known for its role as molecular scissors that make precise cuts in DNA at specific locations to create space for incorporating new genetic material. CRISPR-Cas9 offers advantages in terms of speed, cost-efficiency, accuracy, and overall effectiveness compared to other existing genome editing methods. Companies such as Crispr Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine are actively investing in CRISPR technology, reflecting the significant impact and potential of this cutting-edge gene editing approach.

In February 2024, Ginkgo Bioworks, a US-based biotechnology company, acquired Patch Biosciences for an undisclosed sum. This acquisition is a significant step in Ginkgo's strategy to strengthen its genetic medicine capabilities, aiming to integrate Patch's AI-driven platform with Ginkgo's current services, including gene therapy, cell therapy, and RNA therapeutics. This move aligns with Ginkgo's broader strategy of expanding its portfolio through acquisitions, particularly of companies focused on molecular medicine and AI-driven drug discovery. Patch Biosciences, a US-based biotechnology company, specializes in gene editing and the development of genetic medicines.

Major companies operating in the gene editing market include AstraZeneca plc, Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare Life Sciences, Agilent Technologies Inc., Lonza Group AG, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., CRISPR Therapeutics, Promega Corporation, GenScript USA Inc., Integrated DNA Technologies Inc., Intellia Therapeutics Inc., DNA Script Inc., Dharmacon Inc., Precision Biosciences Inc., Editas Medicine Inc., OriGene Technologies Inc., Tecan Group Ltd., Sangamo Therapeutics Inc., Horizon Discovery Group plc, Addgene Inc., New England Biolabs Inc., Cellectis SA, Recombinetics Inc., Allele Biotechnology LLC, Transposagen Biopharmaceuticals Inc., Bluebird Bio Inc., Regeneron Pharmaceuticals Inc., Amsbio LLC, Creative Biogene Inc., Synthego Corporation, Beam Therapeutics Inc., Caribou Biosciences Inc., Inscripta Inc., Mammoth Biosciences Inc., Sangon Biotech (Shanghai) Co. Ltd., ToolGen Inc., Mirus Bio LLC.

Gene editing refers to the innovative technology enabling precise changes in the genetic code at specific locations within a genome. This cutting-edge process involves manipulating genetic material in various fields such as cell line engineering, animal genetic engineering, and plant genetic engineering.

The primary gene editing technologies include CRISPR, TALEN, and ZFN. CRISPR, a groundbreaking method, empowers geneticists and medical researchers to edit sections of the genome by altering, inserting, or removing DNA sequences accurately. These technologies find applications across biotechnology, pharmaceuticals, and contract research organizations, serving purposes in animal genetic engineering, plant genetic engineering, and cell line engineering.

The gene editing market research report is one of a series of new reports that provides gene editing market statistics, including gene editing industry global market size, regional shares, competitors with a gene editing market share, detailed gene editing market segments, market trends and opportunities, and any further data you may need to thrive in the gene editing industry. This gene editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the gene editing market in 2024. Western Europe was the second largest region in the global gene editing market share. The regions covered in the gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gene editing market includes revenue earned by zinc-finger nucleases (ZFNs) and homing endonucleases or meganucleases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.